Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24500822 | 0.88 | PPARA (0.40) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL22425825 | 0.85 | PPARA (0.40) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL24496961 | 0.82 | PPARA (0.37) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL29711764 | 0.82 | PPARA (0.37) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL29711746 | 0.82 | PPARA (0.37) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL24500704 | 0.81 | PPARA (0.44) | PPARAPPARGCTSSAAK1KDM4E | |
| SCHEMBL24500706 | 0.75 | PPARA (0.36) | PPARAPPARGCTSSAAK1KLK7 | |
| SCHEMBL14126538 | 0.72 | CACNA1B (0.53) | PPARAPPARGCTSSALDH1A1RAB9A | |
| SCHEMBL506388 | 0.71 | PPARA (0.67) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL23390363 | 0.71 | PPARA (0.67) | PPARAPPARGCTSSKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | PPARA 2062/4885PPARG 2574/4885CTSS 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.